Výsledky vyhledávání - "I V, Ignat'ev"

Retrofitting the schematic and layout solutions of the condensate-feedwater path and its equipment of turbine units at thermal and nuclear power stations

Autor: Yu. V. Shalkevich, E. V. Kovalenko, N. N. Trifonov, I. V. Ignat’ev

Publikováno v: Thermal Engineering. 53:110-112

It is shown that the efficiency of the equipment of a regeneration system already in service can be improved through operating it at sliding pressure. The limiting operating conditions of the heat exchanger-pipeline-pump system are determined. The re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2dd13874958a41512f77d78d69a81395
https://doi.org/10.1134/s0040601506020066

Zobrazit plný text záznamu

[CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications]

Autor: D A, Sychev, I V, Ignat'ev, E S, Kropacheva, N V, Emel'ianov, V V, Milovanova, Iu A, Naumova, A V, Kosovskaia, O B, Dobrovol'skiĭ, A I, Tashenova, E P, Panchenko, V G, Kukes

Publikováno v: Vestnik Rossiiskoi akademii meditsinskikh nauk. (3)

The study included 25 patients at high risk of thromboembolic complications. All of them were treated with acenocoumarol for 6 months under control of the frequency of hemorrhage and episodes of severe hypocoagulation (a more than 3-fold rise in INR)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ab14ccf421987747f8da03af0235c94e
https://pubmed.ncbi.nlm.nih.gov/21544933

Zobrazit plný text záznamu

[Anticoagulant action and safety of warfarin dosing based on pharmacogenetic testing: results of the first Russian prospective pilot study]

Autor: D A, Sychev, I M, Antonov, I V, Ignat'ev, Iu V, Naumova, V A, Dmitriev, E S, Kropacheva, O B, Dobrovol'skiĭ, E P, Panchenko, I A, Tashenova, V G, Kukes

Publikováno v: Kardiologiia. 50(5)

Aim of the study was to compare numbers of episodes of excess hypocoagulation and bleeding with warfarin dosing based on pharmacogenetic testing and traditional method in patients with high risk of thromboembolic complications. In 76 patients (43 men

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::73633cdaa061587befcb085c46a17f9b
https://pubmed.ncbi.nlm.nih.gov/20831047

Zobrazit plný text záznamu

[Importance of genetic polymorphism of cytochrome P450 isoenzymes for the choice and regimes of antidepressant and antipsychotic dosing on an individual basis]

Autor: M I, Savel'eva, D A, Sychev, R E, Kazakov, I V, Ignat'ev, A, Tishenova, N A, Gasanov, G V, Ramenskaia, V G, Kukes

Publikováno v: Klinicheskaia meditsina. 86(11)

Polymorphism of P450 2D6 (CYP2D6) gene is one of the causes of altered activity of enzymes controlling metabolism of medicinal products (MP), specifically increasing and decreasing biotransformation of xenobiotics. These changes result either in a ri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3e0522c5fc7b3afcaa7ed99865e4a535
https://pubmed.ncbi.nlm.nih.gov/19177788

Zobrazit plný text záznamu

[Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin]

Autor: Iu A, Mikheeva, E S, Kropacheva, I V, Ignat'ev, Iu M, Bulytova, G V, Ramenskaia, D A, Sychev, A B, Dobrovol'skiĭ, E P, Panchenko

Publikováno v: Kardiologiia. 48(3)

Aim of the study was to investigate frequency and influence of alleles CYP2C9*2 and CYP2C9*3 on pharmacokinetics, pharmacodynamics and dosing regimen of warfarin and on development of hemorrhagic complications. We included 84 patients (mean age 62,8

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::87e40eb0a8f1da90c97df00a5e51e9e7
https://pubmed.ncbi.nlm.nih.gov/18429757

Zobrazit plný text záznamu

[The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation]

Autor: D A, Sychev, Iu A, Mikheeva, E S, Kropacheva, I V, Ignat'ev, Iu M, Bulytova, G V, Ramenskaia, A B, Dobrovol'skiĭ, E P, Panchenko, V G, Kukes

Publikováno v: Klinicheskaia meditsina. 85(1)

CYP2C9 is the main enzyme participating in warfarin metabolism, of which genetic polymorphism is typical. The aim of the study was to investigate the influence of having allelic variants CYP2C9*2 and CYP2C9*3 on the pharmacokinetics, dosage regimen,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8b98414ff868fe3c3d5255b1f84bf7f2
https://pubmed.ncbi.nlm.nih.gov/17419358

Zobrazit plný text záznamu

[Pharmacogenetics of indirect anticoagulants: value of genotype for improvement of efficacy and safety of therapy]

Autor: D A, Sychov, E S, Kropacheva, I V, Ignat'ev, Iu M, Bulytova, A B, Dobrovol'skiĭ, E P, Panchenko, V G, Kukes

Publikováno v: Kardiologiia. 46(7)

The review is devoted to the contemporary state of the problem of pharmacogenetics of indirect anticoagulants. At present there are data about effects of allele variants of CYP2C9, VKORC1, APOE genes on efficacy and safety of therapy with indirect an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::19a78d2d87324338310691dc5de403f8
https://pubmed.ncbi.nlm.nih.gov/16883270

Zobrazit plný text záznamu

[The clinical pharmacology of beta-adrenoblockers]

Autor: D A, Sychev, G V, Ramenskaia, I V, Ignat'ev, S A, Smirnikhina, R E, Kazakov, V G, Kukes

Publikováno v: Klinicheskaia meditsina. 84(3)

Beta-adrenoblockers (BAB) are highly-effective pharmaceuticals used broadly in treatment of cardial diseases. Response to BABs is known to display interindividual variability; pre-treatment analysis of allelic gene variants responsible for BAB pharma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::88e893eadfdf00780606f86e224f080e
https://pubmed.ncbi.nlm.nih.gov/16758913

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání